CML is usually diagnosed in the chronic phase (CP-CML), which can be managed long-term using BCR::ABL1-antagonising tyrosine kinase inhibitors (TKIs). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.